{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T03:47:10Z","timestamp":1790567230895,"version":"4.1.0"},"reference-count":26,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T00:00:00Z","timestamp":1712361600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Cosmetic Dermatology"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Melasma is a chronic hyperpigmentation disorder, and its treatment poses a challenge to dermatologists due to its chronicity and resistance to conventional therapies. Oral isoniazid is used for the treatment of tuberculosis. One of us had previously showed that topical isoniazid exerts a strong depigmenting action in animal models. In this clinical trial, we assessed the therapeutic effect of topical isoniazid on melasma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Twenty female patients suffering from epidermal melasma were enrolled and divided equally into two groups. The treatment group received topical isoniazid 10%, and the control group received the cold cream vehicle as the placebo. All participants were advised to avoid sunlight and used SPF 50 sunscreen. Patients applied topical agents once daily at night for 3\u2009months. The melanin and erythema indices were measured by colorimetric evaluations at baseline and after 4, 8, and 12\u2009weeks of treatment. At these time points, the (mMASI) score was also determined, as was the subjective evaluation through Melasma Quality of Life Scale (MELASQOL) scores. Blood tests were performed to evaluate CBC and the liver enzymes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>All patients completed the 12\u2010week study. In the treatment group, a significant decrease in melanin index from 63.77\u2009\u00b1\u20096.27 at baseline to 55.92\u2009\u00b1\u20095.79 was recorded <jats:italic>(p<\/jats:italic>\u2009=\u20090.001). Very minimal clinical changes were also seen in the control group and melanin index was decreased from 62.65\u2009\u00b1\u20092.23 to 61.25\u2009\u00b1\u20092.34 (<jats:italic>p<\/jats:italic>\u2009=\u20090.004). Clinically significant differences were observed in the rate of changes between both groups. These findings indicate that topical isoniazid has significant depigmenting effects compared to the placebo (<jats:italic>p<\/jats:italic>\u2009=\u20090.001). The erythema index remained unchanged in both groups. In the treatment group, the mMASI score was 5.63\u2009\u00b1\u20093.28 at baseline and 2.13\u2009\u00b1\u20091.71 at the last follow\u2010up, significantly reduced compared to the control group (<jats:italic>p<\/jats:italic>\u2009=\u20090.002). The MELASQOL score indicated a significant improvement in the quality of life in the treatment group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This clinical trial shows for the first time that topical isoniazid is effective in treating melasma. Further clinical trials are necessary to confirm the efficacy and tolerability of topical isoniazid in comparison with other skin\u2010depigmenting compounds.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jocd.16320","type":"journal-article","created":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T08:15:17Z","timestamp":1712391317000},"page":"2636-2643","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Topical isoniazid as a novel treatment for melasma: A randomized, double\u2010blind, vehicle\u2010controlled clinical trial"],"prefix":"10.1111","volume":"23","author":[{"given":"Najmeh","family":"Ahramiyanpour","sequence":"first","affiliation":[{"name":"Department of Dermatology Bushehr University of Medical Sciences  Bushehr Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Mahmoudi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Afzalipour Faculty of Medicine, Afzalipour Hospital Kerman University of Medical Sciences  Kerman Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazanin Zeinali","family":"Nezhad","sequence":"additional","affiliation":[{"name":"Physiology Research Center Kerman University of Medical Science  Kerman Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payam","family":"Khazaeli","sequence":"additional","affiliation":[{"name":"School of Pharmacy Kerman University of Medical sciences  Kerman Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rezvan","family":"Amiri","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Afzalipour Faculty of Medicine, Afzalipour Hospital Kerman University of Medical Sciences  Kerman Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behrooz","family":"Kasraee","sequence":"additional","affiliation":[{"name":"Department of Dermatology Geneva University Hospital  Geneva Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,4,6]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S396272"},{"key":"e_1_2_10_3_1","first-page":"1","article-title":"An intelligent diagnostic model for melasma based on deep learning and multimode image input","volume":"13","author":"Liu L","year":"2022","journal-title":"Dermatol Ther"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2021.1914313"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-019-00488-w"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2007.04.006"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrgentox.2014.10.009"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.13203"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2017.1351608"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200303-390OC"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.2174\/15672050113109990203"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2019.02.016"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1159\/000066439"},{"key":"e_1_2_10_14_1","unstructured":"KasraeeB.Use of substituted pyridines as skin depigmenting agents. Patent (WO2013030794A2) 12.08.20122012."},{"key":"e_1_2_10_15_1","unstructured":"SaraA PourahmadiM AslaniFS KasraeeB.Topical isonicotinic acid hydrazide (isoniazid) as a new skin depigmenting compound. Poster 505 in 9th Spring Symposium of the EADV (European Academy of Dermatology and Venerology)\u2014Verona Italiy2012."},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12033-020-00292-6"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.62.1.71"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2003.01621.x"},{"key":"e_1_2_10_19_1","volume-title":"InStatPearls [Internet]","author":"Schwartz C","year":"2022"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.12769"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714284"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00044-011-9948-y"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.2174\/138920007782798216"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00044-023-03039-5"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1159\/000336777"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2004.11.009"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000391019.10661.66"}],"container-title":["Journal of Cosmetic Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jocd.16320","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T11:20:10Z","timestamp":1735298410000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jocd.16320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,6]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1111\/jocd.16320"],"URL":"https:\/\/doi.org\/10.1111\/jocd.16320","archive":["Portico"],"relation":{},"ISSN":["1473-2130","1473-2165"],"issn-type":[{"value":"1473-2130","type":"print"},{"value":"1473-2165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,6]]},"assertion":[{"value":"2024-01-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}